博雅生物(300294) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for the current period is ¥649,526,615.39, a decrease of 5.04% compared to the same period last year[1] - The net profit attributable to shareholders for the current period is ¥138,149,317.69, down 0.93% year-on-year[1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is ¥103,864,621.69, a decrease of 4.20% compared to the same period last year[1] - Total operating revenue for the third quarter was CNY 2,190,398,869.51, an increase of 5.3% compared to CNY 2,082,744,315.52 in the previous year[41] - Net profit attributable to shareholders of the parent company reached CNY 464,067,798.65, representing a 10.9% increase from CNY 418,279,088.07 in the prior year[46] - The net profit for the third quarter was 474,089,330.24, an increase of 10.6% compared to 428,899,020.70 in the previous year[54] - Operating profit increased to 577,182,286.70, reflecting a growth of 14.2% from 505,255,213.36 year-over-year[54] Assets and Liabilities - The total assets at the end of the current period amount to ¥8,182,958,918.52, reflecting a 1.86% increase from the end of the previous year[1] - Total assets increased to CNY 8,182,958,918.52, compared to CNY 8,033,175,408.45 at the end of the previous period[41] - Total liabilities decreased to CNY 610,247,338.68 from CNY 748,348,858.19 in the previous year[41] - Non-current liabilities totaled CNY 53,977,140.53, an increase from CNY 43,011,597.58 in the previous year[41] - The company’s total equity increased to CNY 7,572,711,579.84 from CNY 7,284,826,550.26 in the previous year[41] Cash Flow - Cash flow from operating activities netted 525,706,132.68, compared to 377,007,297.33 in the previous year, marking a 39.4% increase[55] - Cash inflow from investment activities totaled 3,992,659,220.89, up from 3,448,467,134.16, indicating a growth of 15.8%[55] - The cash flow from investment activities showed a net outflow of -519,774,432.72, an improvement from -778,543,985.54 in the previous year[57] Research and Development - Research and development expenses for the first nine months of 2023 are ¥48,042,073.01, an increase of 34.85% compared to the same period last year[7] - Research and development expenses rose to 48,042,073.01, up 34.7% from 35,626,723.74 in the same period last year[54] - The company’s development expenses increased by 43.85% to CNY 54,494,597.21 due to increased R&D investments[29] Equity Transactions - The company transferred 75% equity of Guangdong Fuda Pharmaceutical Co., Ltd. for ¥364,764,150 to China Resources Pharmaceutical Group Co., Ltd.[15] - The company transferred 75% equity of Guangdong Fuda Pharmaceutical Co., Ltd. and no longer holds any shares in it[26] - The company sold 89.681% equity of Guizhou Tianan Pharmaceutical Co., Ltd. for CNY 260.36 million to China Resources Double Crane Pharmaceutical Co., Ltd.[28] Other Income and Expenses - The company reported a significant increase in other income, which rose by 240.53% to ¥18,829,417.54 due to increased government subsidies[7] - The fair value change income increased by 251.95% to ¥75,712,202.18, attributed to gains from financial products[7] - The company reported a total tax expense of 101,112,893.62, which is an increase from 75,129,153.47, reflecting a rise of 34.6%[54] Shareholder Information - The company’s total number of common stock shareholders at the end of the reporting period was 22,290[24] - The largest shareholder, China Resources Pharmaceutical Group Co., Ltd., holds 29.28% of the shares[24] Inventory and Receivables - Accounts receivable decreased by 44.11% to CNY 258,064,802.50 due to the divestment of Fuda Pharmaceutical and improved cash collection[29] - Other receivables increased by 252.08% to CNY 354,264,211.27 primarily due to the receivable from the transfer of Fuda Pharmaceutical equity[29] - The company’s inventory decreased to CNY 579,701,942.68 from CNY 666,962,605.02 in the previous year[41] Future Plans - The company plans to establish single plasma collection stations in Taihe County and Le Ping City, pending regulatory approvals[37] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[54]